Skip to content

Educational action for adults with type 2 Diabetes in primary care with a low-carbohydrate diet

Educational intervention for adults with type 2 Diabetes in primary care on low-carbohydrate eating:a randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-39xwyzr
Enrollment
Unknown
Registered
2025-03-10
Start date
2024-07-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diet

Interventions

This is a 2-arm parallel randomized clinical trial. Experimental group: 30 patients with Type 2 Diabetes without using insulin will receive hybrid low-carb dietary education (via smartphone app and in

Sponsors

Universidade Estadual do Oeste do Paraná
Lead Sponsor
Prefeitura Municipal de Francisco Beltrão
Collaborator

Eligibility

Age
40 Years to 89 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with Type 2 Diabetes without using insulin, aged between 40 and 89 years and with glycated hemoglobin levels equal to or above 6.5%. It may or may not have arterial hypertension as a comorbidity. Must have full access to the internet and have a smartphone application for individual or group communication

Exclusion criteria

Exclusion criteria: Those who have other forms of Diabetes, vegans, vegetarians, who have had bariatric surgery, with severe cardiovascular disease or diagnosed kidney disease, with a condition that affects their ability to participate, pregnant and lactating women, being on a weight loss program, in risk of an eating disorder or with a baseline glycated hemoglobin measurement of less than 6.5%

Design outcomes

Primary

MeasureTime frame
It is expected to find changes in glycemic control and glycated hemoglobin levels compared to standard treatment.

Secondary

MeasureTime frame
It is expected to verify changes in food intake, body mass index and waist circumference, HOMA-IR and quality of life of patients with type 2 Diabetes. In addition, it will evaluate changes in antidiabetic medications and possible changes in the hypertension condition blood flow in patients with DM2 suffering from this comorbidity.

Countries

Brazil

Contacts

Public ContactGisely Balbinot

Universidade Estadual do Oeste do Paraná

giselysanagiotto@gmail.com+55046988001103

Outcome results

None listed

Source: REBEC (via WHO ICTRP)